Early treatment trial for early schizophrenia warning signs
Treatments studied
Part of Mental health clinical trials.
This Phase 2 study tests an NMDA-enhancer medicine to see if it can help people who are in the early “prodromal” stage—when symptoms are starting but full schizophrenia is not diagnosed yet. It aims to reduce or prevent worsening symptoms over the study period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early warning symptoms of schizophrenia (prodromal syndrome), such as weaker but increasing unusual thoughts, brief episodes of psychosis, or genetic risk with decline
- After a 6-week run-in period, your symptoms are still present based on a symptom score (at least 20 on the SOPS total score)
- You can be on antipsychotic medication only if the dose has stayed the same for at least 4 weeks before screening, and the dose stays the same during the study
- If you are not on antipsychotics, you must not start them during the study
- You (and a parent, if you are under 20) can and will sign written consent and follow study steps
- You do not have certain conditions that would rule you out, like schizophrenia diagnosis, intellectual disability, substance use disorder, or significant brain/neurologic illness
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether NAC (a nutrient-like supplement) can reduce symptoms in people who are at high risk for developing psychosis. It may help by testing a safer, non-standard treatment approach for early warning signs.
This trial tests a staged (“step-based”) mental health program for people ages 12–25 who have early warning signs that could develop into psychosis. It may help by targeting symptoms early and reducing the chance of worsening over time.
This Phase 2 trial tests a single medicine intended to help people with schizophrenia who cannot take standard antipsychotic medications due to side effects or poor response. It may help reduce schizophrenia symptoms, but whether you can join depends on your diagnosis, medication history, and health conditions.
This Phase 2 trial tests whether adding an “NMDA-enhancing” treatment plus an antioxidant can improve ongoing schizophrenia symptoms over 12 weeks. It’s meant for people who still have symptoms even though their usual antipsychotic dose has been stable for at least 3 months.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This study tests whether a medication that boosts brain NMDA receptors can improve negative symptoms in schizophrenia, and looks at differences between men and women. It is for people with stable schizophrenia who still have mostly flat mood or low motivation.
Hear when a new Prodromal Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.